Trelegy Ellipta vs. Breo for COPD
UpdatedFebruary 29, 2024
🔑 Key Takeaways
- Trelegy Ellipta contains three active ingredients (fluticasone, vilanterol, and umeclidinium), while Breo Ellipta contains two (fluticasone and vilanterol). The additional anticholinergic in Trelegy aims to provide more robust symptom management.
- Both are taken as an oral inhalation once daily, with the maximum dose being one inhalation per 24 hours. Proper use and storage of the inhaler device are essential.
- In a large clinical trial, Trelegy Ellipta showed a 15% greater reduction in COPD flare-ups and better lung function over one year than Breo Ellipta. It also improved the quality of life versus Breo.
- Trelegy Ellipta demonstrated a superior improvement in lung function for asthma patients versus Breo Ellipta in another major trial. However, responses can vary individually.
- Both drugs have potentially serious side effects like breathing problems, infections, vision changes, and hormonal issues. Trelegy also lists tremors and nervousness. The common side effects differ somewhat.
- Trelegy Ellipta costs around $323 for 28 doses, while Breo Ellipta costs around $170 for 28 doses. However, Breo's generic is more expensive. Discounts can reduce costs.
- Our prescription savings service, Cuverd®, searches smarter than other options to find the best pricing on medications like these COPD treatments.
The choice between the Trelegy Ellipta and Breo Ellipta would depend on the specific respiratory condition and the patient's medical history, including any allergies or contraindications to the components of each medication. Patients must adhere to their prescribed dosage and consult their healthcare providers for any concerns or adjustments in treatment.
It's crucial to emphasize that individual responses may vary, and the choice between Trelegy and Breo should be made in consultation with a healthcare professional who can assess the patient's specific symptoms, medical history, and overall health. Personalized treatment plans are essential to ensure optimal outcomes for individuals with COPD or asthma, taking into account the unique characteristics of each patient's condition.